Immucell Corp /DE/ SEC filings ICCC
Immucell Corp /DE/ has 795 filings in SEC EDGAR's recent list, going back to Aug 3, 1995. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 11, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2026 | Jun 11, 2026 |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 12, 2025 |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 13, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 15, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2023 | Apr 18, 2023 |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 15, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2022 | Apr 12, 2022 |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 16, 2021 |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 10, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2020 | Apr 14, 2020 |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 13, 2019 |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 14, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2018 | Apr 16, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 14, 2017 |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 15, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2016 | Jun 15, 2016 |
| DEF 14A | Proxy statement | Apr 24, 2015 | Jun 11, 2015 |
| DEF 14A | Proxy statement | Apr 24, 2014 | Jun 11, 2014 |
| DEF 14A | Proxy statement | Apr 18, 2013 | Jun 12, 2013 |
| DEF 14A | Proxy statement | Apr 25, 2012 | Jun 14, 2012 |
| DEFA14A | Additional proxy material | Apr 18, 2011 | — |
| DEF 14A | Proxy statement | Apr 18, 2011 | Jun 15, 2011 |
| DEF 14A | Proxy statement | Apr 20, 2010 | Jun 16, 2010 |
| DEF 14A | Proxy statement | Apr 17, 2009 | Jun 12, 2009 |
| DEF 14A | Proxy statement | Apr 17, 2008 | Jun 6, 2008 |
| DEF 14A | Proxy statement | Apr 17, 2007 | Jun 7, 2007 |
| DEF 14A | Proxy statement | Apr 21, 2006 | Jun 7, 2006 |
| DEF 14A | Proxy statement | Apr 19, 2005 | Jun 8, 2005 |
| DEF 14A | Proxy statement | Apr 16, 2004 | Jun 8, 2004 |
| DEF 14A | Proxy statement | Apr 29, 2003 | Jun 11, 2003 |
| DEF 14A | Proxy statement | Apr 29, 2002 | Jun 12, 2002 |
| DEF 14A | Proxy statement | Apr 24, 2001 | Jun 13, 2001 |
| DEF 14A | Proxy statement | Apr 28, 2000 | Jun 22, 2000 |
| DEF 14A | Proxy statement | Apr 26, 1999 | Apr 26, 1998 |
| DEF 14A | Proxy statement | Apr 20, 1998 | Apr 20, 1998 |
| DEF 14A | Proxy statement | Apr 25, 1997 | Apr 25, 1997 |
| DEF 14A | Proxy statement | Apr 26, 1996 | Jun 28, 1996 |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ICCC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Portland, ME
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 811641
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.